- Home
- MNOV vs NRXP Comparison
MNOV vs NRXP Comparison
Compare MNOV & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- NRXP
- Stock Information
- Founded
- MNOV 2000
- NRXP 2015
- Country
- MNOV United States
- NRXP United States
- Employees
- MNOV N/A
- NRXP N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- NRXP Health Care
- Exchange
- MNOV Nasdaq
- NRXP Nasdaq
- Market Cap
- MNOV 68.2M
- NRXP 58.5M
- IPO Year
- MNOV 2005
- NRXP N/A
- Fundamental
- Price
- MNOV $1.34
- NRXP $2.34
- Analyst Decision
- MNOV Strong Buy
- NRXP Strong Buy
- Analyst Count
- MNOV 2
- NRXP 4
- Target Price
- MNOV $7.00
- NRXP $29.25
- AVG Volume (30 Days)
- MNOV 62.5K
- NRXP 463.4K
- Earning Date
- MNOV 08-14-2025
- NRXP 08-18-2025
- Dividend Yield
- MNOV N/A
- NRXP N/A
- EPS Growth
- MNOV N/A
- NRXP N/A
- EPS
- MNOV N/A
- NRXP N/A
- Revenue
- MNOV $134,599.00
- NRXP N/A
- Revenue This Year
- MNOV N/A
- NRXP N/A
- Revenue Next Year
- MNOV N/A
- NRXP $231.16
- P/E Ratio
- MNOV N/A
- NRXP N/A
- Revenue Growth
- MNOV N/A
- NRXP N/A
- 52 Week Low
- MNOV $1.13
- NRXP $1.10
- 52 Week High
- MNOV $2.55
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- MNOV 52.82
- NRXP 41.81
- Support Level
- MNOV $1.32
- NRXP $2.40
- Resistance Level
- MNOV $1.43
- NRXP $2.83
- Average True Range (ATR)
- MNOV 0.04
- NRXP 0.20
- MACD
- MNOV 0.00
- NRXP 0.01
- Stochastic Oscillator
- MNOV 50.00
- NRXP 26.92
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.